Seeking Alpha

KaloBios Pharma -38% AH on decision to stop asthma study

  • KaloBios Pharmaceuticals (KBIO) -38.7% AH after saying it will discontinue development of its KB003 treatment for severe asthma following initial data evaluation of a Phase 2 study which didn't meet its primary clinical endpoint of improvement when compared to placebo.
  • KBIO had targeted the severe asthma population, which represents 5%-10% of the world's total asthma population of ~300M people.
  • CEO David Pritchard says KBIO will refocus efforts on advancing its other treatments under development, including an oncology program and a potential treatment for cystic fibrosis.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector